Fastest Growing Stocks
KRYS is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
KRYSTAL BIOTECH INC (KRYS) Stock Price & Overview
NASDAQ:KRYS • US5011471027
Current stock price
272.66 USD
-3.84 (-1.39%)
At close:
272.66 USD
0 (0%)
After Hours:
The current stock price of KRYS is 272.66 USD. Today KRYS is down by -1.39%. In the past month the price increased by 9.03%. In the past year, price increased by 62.24%.
KRYS Key Statistics
52-Week Range122.8 - 298.302
Current KRYS stock price positioned within its 52-week range.
1-Month Range242 - 278.86
Current KRYS stock price positioned within its 1-month range.
- Market Cap
- 8.027B
- P/E
- 39.80
- Fwd P/E
- 35.02
- EPS (TTM)
- 6.85
- Dividend Yield
- N/A
KRYS Stock Performance
Today
-1.39%
1 Week
+0.99%
1 Month
+9.03%
3 Months
-3.15%
Longer-term
6 Months +46.49%
1 Year +62.24%
2 Years +78.07%
3 Years +224.60%
5 Years +243.23%
10 Years N/A
KRYS Stock Chart
KRYS Stock Screens
KRYS currently appears in the following ChartMill screener lists.
Strong Buy Rated Stocks
KRYS is part of our Strong Buy Rated Stocks screen, indicating it has a strong buy ratings from analysts and supporting business quality.
Breakout Setups
KRYS appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
CAN SLIM Stocks
KRYS is part of our CAN SLIM stock list, indicating it is suited for high growth momentum investing and is a technical leader.
KRYS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to KRYS. When comparing the yearly performance of all stocks, KRYS is one of the better performing stocks in the market, outperforming 83.56% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
KRYS Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to KRYS. KRYS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
KRYS Earnings
On February 17, 2026 KRYS reported an EPS of 1.7 and a revenue of 107.11M. The company beat EPS expectations (18.32% surprise) and missed revenue expectations (-0.31% surprise).
Next Earnings DateMay 11, 2026
Last Earnings DateFeb 17, 2026
PeriodQ4 / 2025
EPS Reported$1.70
Revenue Reported107.105M
EPS Surprise 18.32%
Revenue Surprise -0.31%
KRYS Forecast & Estimates
18 analysts have analysed KRYS and the average price target is 320.08 USD. This implies a price increase of 17.39% is expected in the next year compared to the current price of 272.66.
For the next year, analysts expect an EPS growth of 13.66% and a revenue growth 36.54% for KRYS
Analysts
Analysts85.56
Price Target320.08 (17.39%)
EPS Next Y13.66%
Revenue Next Year36.54%
KRYS Groups
Sector & Classification
KRYS Financial Highlights
Over the last trailing twelve months KRYS reported a non-GAAP Earnings per Share(EPS) of 6.85. The EPS increased by 129.1% compared to the year before.
Income Statements
Revenue(TTM)389.13M
Net Income(TTM)204.83M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 52.64% | ||
| ROA | 15.36% | ||
| ROE | 16.8% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%11.84%
Sales Q2Q%17.52%
EPS 1Y (TTM)129.1%
Revenue 1Y (TTM)33.95%
KRYS Ownership
Ownership
Inst Owners97.26%
Shares29.44M
Float25.45M
Ins Owners11.52%
Short Float %12.44%
Short Ratio10.84
KRYS Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 360.314B | ||
| AMGN | AMGEN INC | 15.1 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.94 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.19 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.53 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KRYS
Company Profile
Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 295 full-time employees. The company went IPO on 2017-09-20. The firm is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Company Info
IPO: 2017-09-20
KRYSTAL BIOTECH INC
2100 Wharton St Ste 701
Pittsburgh PENNSYLVANIA 15203 US
CEO: Krish S. Krishnan
Employees: 295
Phone: 14125865830
KRYSTAL BIOTECH INC / KRYS FAQ
Can you describe the business of KRYSTAL BIOTECH INC?
Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 295 full-time employees. The company went IPO on 2017-09-20. The firm is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
What is the current price of KRYS stock?
The current stock price of KRYS is 272.66 USD. The price decreased by -1.39% in the last trading session.
Does KRYSTAL BIOTECH INC pay dividends?
KRYS does not pay a dividend.
How is the ChartMill rating for KRYSTAL BIOTECH INC?
KRYS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
How is the market expecting KRYS stock to perform?
18 analysts have analysed KRYS and the average price target is 320.08 USD. This implies a price increase of 17.39% is expected in the next year compared to the current price of 272.66.
Can you provide the PE ratio for KRYS stock?
The PE ratio for KRYSTAL BIOTECH INC (KRYS) is 39.8. This is based on the reported non-GAAP earnings per share of 6.85 and the current share price of 272.66 USD.
What is the Short Interest ratio of KRYSTAL BIOTECH INC (KRYS) stock?
The outstanding short interest for KRYSTAL BIOTECH INC (KRYS) is 12.44% of its float.